launch mvasi biosimilar bevacizumab kanjinti biosimilar
trastuzumab us pioneer entrant two potenti multi-billion dollar
biosimilar market believ favor time launch facilit
recent district court denial motion restrain order preliminari
injunct opinion significantli de-risk surpris launch
therebi unlock potenti upsid sharehold sever biosimilar
product includ amgevita biosimilar adalimumab success
penetr european market us biosimilar market remain uncertain
updat model script adjust yet conserv hold
factor revenu mvasi kanjinti us bullish thesi
base stabl outlook revenu exhibit detail insid
consid biosimilar strategi import hedg potenti loss
enbrel lose enbrel patent judg decis due day
follow appeal process like take anoth month revenu could
protect biosimilar market impedi us potenti sale mvasi
kanjinti could off-set enbrel eros case biosimilar overcom
revenu forecast gener consensu total
revenu estim slightli declin exhibit
model oper margin expans go
believ cost cut manag control margin expans
could facilit synergist acquisit
optimist pipelin includ kra inhibitor
nsclc bcma bite r/rmm recent deliv
impress clinic data also encourag growth
driver includ prolia repatha aimovig expect drive mix shift
exhibit support thesi margin expans
risk-adjust us sale forecast enbrel declin
growth factor forecast decreas
enbrel growth factor forecast
around consensu contribut per share hypothet
look forward result expect includ import insight
prolia repatha aimovig continu launch trajectori also expect pipelin
updat timelin import clinic program addit color
biosimilar progress includ mvasi kanjinti us make small
model adjust reiter outperform rate pt
year price histori
biotechnolog
discov
develop manufactur market
cancer autoimmun
diseas specialti market
analyst certif import disclosur see disclosur
estim amgen top line remain rel stabl
margin improv sg decreas
percentag sale expect volum increas growth
product continu increas market penetr pipelin
estim revenu remain rel flat
next year margin continu expand
manag track record financi disciplin
top line believ posit maintain long-term
revenu stabil matur product declin new product
continu grow pipelin deliv steadi flow new
product addit offer dividend yield
believ provid valuat support
updat data kra inhibitor major
updat data bcma bite
data bcma hle bite
data bite
data inh iv
data inh oral
estim sell price two experiment product
low price increas exist product would
meaning upsid earn estim
experiment compound launch sooner
estim would result addit upsid estim
repatha growth slow pipelin asset fail launch
estim gradual declin revenu ep scenario
estim stock could valu rang
next month
price target base dcf valuat assum wacc residu growth rate
due declin in-lin product off-set new product pipelin long term see top line essenti stabl
forecast peak sale tezepelumab base probabl success base probabl
success omecamtiv base probabl success
believ greatest risk stock next five year disrupt continu success repatha fda
approv experiment therapi romosozumab continu success launch aimovig migrain biosimilar abp abp
abp key risk project would occur repatha growth slow experiment therapi biosimilar fail
launch scenario estim stock could valu rang next month
exhibit consensu estim total revenu growth factor product neulasta
aranesp epogen nplate enbrel gener in-lin estim
exhibit revenu estim product line
exhibit growth factor enbrel contribut per share sotp analysi
revenu estim pipelinetot hpt secondari ckdprimari denosumaboncologyenbrelgrowth factorsotherdrug/indicationexpect launchpeak sale estim mm npv mm estimate probabl successprob-adjust npv mm sotp p-adj valu sharegrowth hpt secondari equiti outperform
